| Ccr | Creatinine Clearance; 80 - 90 ml/min |
|---|---|
| CCR | Creatine Clearance Rate; 3.0 - 3.5 gm/24 hr |
| CCR | complete continuous remission |
| Ccr, Ccr | creatinine clearance |
| CCRC | comprehensive care retirement community; continuing care retirement community |
| CCRG | Cooperative Cataract Research Group (American) |
| CCRIS | Chemical Carcinogenesis Research Information System |
| CCRN | Critical Care Registered Nurse |
| CCRS | Chemical Carcinogenesis Research Information System |
| CCRT | computer-controlled radiation therapy |
| ACR | Amylase-Creatinine Clearance Ratio &... |
|---|
| CCR | C-C chemokine receptor |
|---|---|
| CCR | Carbon catabolite repression |
| CCR | Clinical Complete Response |
| CCR | Complex chromosome rearrangements |
| CCr | clearance of creatinine |
| CCR | complete clinical remission |
| CCR | complex chromosomal rearrangement |
| CCR | continuous CR |
| CCR | continuous complete remission |
| CCR | creatinine clearance rate |
| CCR1 protein kinase | <enzyme> Acts independently of camp-dependent protein kinase and the transcriptional activator adr1 in controlling yeast adh2 expression Registry number: EC 2.7.10.- Synonym: snf1 protein kinase, glc2 protein, glc2 gene product, snf1 gene product (26 Jun 1999) |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|---|---|---|---|
|
¾¾¾¾¾Ë¿¬Áúݼ¿ - »õâ
|
½ÅdzÁ¦¾à |
Calcium pantothenate, Chondroitin Sodium Sulfate, Cyanocobalamin, Gamma-oryzanol, Nicotinamide, Pyridoxine HCl, Riboflavin tetrabutyrate, Tocopherol Acetate | ÀϹÝÀǾàǰ | ºñ±Þ¿© |
| CCRC |
Casualty Care Research Center: an agency in the Department of Defense that is a national center for research on all aspects of injury control and casualty care
Ãâó: wordnet.princeton.edu/perl/webwn
|
|---|---|
| CCRC |
Continuing care retirement center.
Ãâó: www.meps.ahrq.gov/Data_Pub/NHC_Acronyms.htm
|
| CCR5 coreceptor |
A cell surface receptor found on macrophages that facilitates entry of HIV-1 into these cells. Chemokines released by T cells attempt to compete with HIV by blocking the receptor to prevent infection.
Ãâó:
|
| CCR5 delta 32 genotype |
A mutation that confers a survival advantage and substantial resistance to the human immunodeficiency virus (HIV). Homozygosity for this allele protects adults from HIV-1 after blood and body fluid exposure. Heterozygosity
Ãâó:
|
| CCRC |
Continuing care retirement center.
Ãâó:
|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|